Aurora Spine Reports Record Revenue, Positive EBITDAC in FY 2024
PorAinvest
martes, 29 de abril de 2025, 7:54 am ET1 min de lectura
ACB--
In the fourth quarter, Aurora Spine achieved its largest ever revenue of $4.7 million, a 16.3% improvement from Q4 2023. The company's SiLO-TFX SI joint implant saw a significant increase in sales, growing by 135% in 2024, attributed to investments in surgeon education and the expansion of instrument sets [1].
Aurora Spine also addressed an issue with its stock option plan disclosures, acknowledging that previous management information circulars for the 2023 and 2024 shareholder meetings referenced an outdated version. The correct version, approved by the board in 2022, will be included in the materials for the upcoming annual general meeting of shareholders [1].
The company will hold a conference call on Tuesday, April 29, 2025, at 11:00 a.m. ET/8:00 a.m. PT to discuss these financial results. Participants can join by dialing (844) 861-5497 or (412) 317-5794, with a live webcast also available at this link. A replay of the call will be accessible until May 6, 2025. A 90-day replay of the webcast will also be available [1].
References:
[1] https://www.gurufocus.com/news/2799116/aurora-spine-corporation-schedules-release-of-fourth-quarter-and-fiscal-2024-financial-results-asapf-stock-news
ASG--
TSVT--
Aurora Spine Corporation reported record revenue of $17.6 million for FY 2024, a 21% increase from the previous year. The company also reported its largest ever fourth quarter revenue of $4.7 million, a 16.3% improvement from Q4 2023. Aurora Spine's margins increased to 60.5% in 2024 from 56.5% in 2023, driven by higher sales of proprietary products and lower inventory costs. The company's sales of the SiLO-TFX SI joint implant grew 135% in 2024, driven by investments in surgeon education and the expansion of instrument sets.
Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology, has released its fourth quarter and fiscal year 2024 financial results. The company reported record revenue of $17.6 million for the fiscal year, a 21% increase from the previous year [1]. This growth was driven by strong sales of proprietary products and lower inventory costs, leading to an improvement in margins to 60.5% in 2024 from 56.5% in 2023 [1].In the fourth quarter, Aurora Spine achieved its largest ever revenue of $4.7 million, a 16.3% improvement from Q4 2023. The company's SiLO-TFX SI joint implant saw a significant increase in sales, growing by 135% in 2024, attributed to investments in surgeon education and the expansion of instrument sets [1].
Aurora Spine also addressed an issue with its stock option plan disclosures, acknowledging that previous management information circulars for the 2023 and 2024 shareholder meetings referenced an outdated version. The correct version, approved by the board in 2022, will be included in the materials for the upcoming annual general meeting of shareholders [1].
The company will hold a conference call on Tuesday, April 29, 2025, at 11:00 a.m. ET/8:00 a.m. PT to discuss these financial results. Participants can join by dialing (844) 861-5497 or (412) 317-5794, with a live webcast also available at this link. A replay of the call will be accessible until May 6, 2025. A 90-day replay of the webcast will also be available [1].
References:
[1] https://www.gurufocus.com/news/2799116/aurora-spine-corporation-schedules-release-of-fourth-quarter-and-fiscal-2024-financial-results-asapf-stock-news

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios